Organoplatinum Compounds

"Organoplatinum Compounds" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Organic compounds which contain platinum as an integral part of the molecule.

Descriptor ID	D009944
MeSH Number(s)	D02.691.800
Concept/Terms	Organoplatinum Compounds Organoplatinum Compounds Compounds, Organoplatinum

Below are MeSH descriptors whose meaning is more general than "Organoplatinum Compounds".

Chemicals and Drugs [D]
Organic Chemicals [D02]
Organometallic Compounds [D02.691]
Organoplatinum Compounds [D02.691.800]

Below are MeSH descriptors whose meaning is related to "Organoplatinum Compounds".

Below are MeSH descriptors whose meaning is more specific than "Organoplatinum Compounds".

Organoplatinum Compounds
Carboplatin

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Organoplatinum Compounds" by people in this website by year, and whether "Organoplatinum Compounds" was a major or minor topic of these publications.

Bar chart showing 17 publications over 9 distinct years, with a maximum of 4 publications in 2011

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2004	2	0	2
2006	1	0	1
2007	0	1	1
2008	0	3	3
2009	0	2	2
2011	0	4	4
2012	0	1	1
2016	0	2	2
2020	0	1	1

Below are the most recent publications written about "Organoplatinum Compounds" by people in Profiles.

Staley SA, Tucker K, Newton M, Ertel M, Oldan J, Doherty I, West L, Zhang Y, Gehrig PA. Sarcopenia as a predictor of survival and chemotoxicity in patients with epithelial ovarian cancer receiving platinum and taxane-based chemotherapy. Gynecol Oncol. 2020 03; 156(3):695-700.

View in: PubMed
Navez J, Remue C, Leonard D, Bachmann R, Kartheuser A, Hubert C, Coubeau L, Komuta M, Van den Eynde M, Zech F, Jabbour N. Surgical Treatment of Colorectal Cancer with Peritoneal and Liver Metastases Using Combined Liver and Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: Report from a Single-Centre Experience. Ann Surg Oncol. 2016 12; 23(Suppl 5):666-673.

View in: PubMed
Chapuy CI, Sahai I, Sharma R, Zhu AX, Kozyreva ON. Hyperammonemic Encephalopathy Associated With Fibrolamellar Hepatocellular Carcinoma: Case Report, Literature Review, and Proposed Treatment Algorithm. Oncologist. 2016 Apr; 21(4):514-20.

View in: PubMed
Dong Y, Zhao J, Wu CW, Zhang L, Liu X, Kang W, Leung WW, Zhang N, Chan FK, Sung JJ, Ng SS, Yu J. Tumor suppressor functions of miR-133a in colorectal cancer. Mol Cancer Res. 2013 Sep; 11(9):1051-60.

View in: PubMed
Rauh-Hain JA, Nitschmann CC, Worley MJ, Bradford LS, Berkowitz RS, Schorge JO, Campos SM, del Carmen MG, Horowitz NS. Platinum resistance after neoadjuvant chemotherapy compared to primary surgery in patients with advanced epithelial ovarian carcinoma. Gynecol Oncol. 2013 Apr; 129(1):63-8.

View in: PubMed
Poultsides GA, Bao F, Servais EL, Hernandez-Boussard T, DeMatteo RP, Allen PJ, Fong Y, Kemeny NE, Saltz LB, Klimstra DS, Jarnagin WR, Shia J, D'Angelica MI. Pathologic response to preoperative chemotherapy in colorectal liver metastases: fibrosis, not necrosis, predicts outcome. Ann Surg Oncol. 2012 Sep; 19(9):2797-804.

View in: PubMed
Hunter KU, Feng FY, Griffith KA, Francis IR, Lawrence TS, Desai S, Murphy JD, Zalupski MM, Ben-Josef E. Radiation therapy with full-dose gemcitabine and oxaliplatin for unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys. 2012 Jul 01; 83(3):921-6.

View in: PubMed
Moore N, Houghton J, Lyle S. Slow-cycling therapy-resistant cancer cells. Stem Cells Dev. 2012 Jul 01; 21(10):1822-30.

View in: PubMed
Hesketh PJ, Wright O, Rosati G, Russo M, Levin J, Lane S, Moiseyenko V, Dube P, Kopp M, Makhson A. Single-dose intravenous casopitant in combination with ondansetron and dexamethasone for the prevention of oxaliplatin-induced nausea and vomiting: a multicenter, randomized, double-blind, active-controlled, two arm, parallel group study. Support Care Cancer. 2012 Jul; 20(7):1471-8.

View in: PubMed
Hesketh PJ, Sanz-Altamira P, Bushey J, Hesketh AM. Prospective evaluation of the incidence of delayed nausea and vomiting in patients with colorectal cancer receiving oxaliplatin-based chemotherapy. Support Care Cancer. 2012 May; 20(5):1043-7.

View in: PubMed

People

Explore

Similar Concepts

Top Journals